Introduction
The European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology (UEG) have identified quality of endoscopy as a major priority and we described our rationale for this in a first manuscript that also addressed the methodology of the quality initiative process. 1 The identification of upper gastrointestinal (UGI) performance measures presents a considerable challenge, in contrast to the situation with colonoscopy for instance, where several performance measures (inspection time, adenoma detection rate, and interval cancers, among others) have been identified over the last decade. 2, 3 Following the Quality in UGI Endoscopy meeting held in Lisbon in 2013, it was clear that there was a need to identify performance measures for the UGI tract, and that quality standards could be identified although there is a paucity of evidence. This lack of evidence helps however to identify research priorities for the development of clinical trials that will further validate and substantiate the implementation of performance measures.
The aim therefore of the UGI working group was twofold: (a) to identify performance measures for UGI endoscopy; (b) to identify the evidence or absence of evidence that would develop the research priorities in this field.
We used an innovative methodology to facilitate the quality initiative process, which combined a thorough search and standardized evaluation of the available evidence for each clinical question, followed by a Delphi process (http://is.njit.edu/pubs/delphibook/delphibook. pdf) using an online platform. 4, 5 This online platform permitted iterative rounds of modification and comment by all members of the UGI working group until agreement was reached on the performance measure. We now report these newly identified performance measures.
Methodology
We previously described the multistep process for the methodology to develop performance measures. 1 Briefly, following the Lisbon meeting in 2013, a list of 56 possible performance measures was distributed to all of the working group members for comments, suggestions, and shortcomings in September 2014. Every participant was required to comment on all of the proposed performance measures during teleconferences that took place between 1 October-18 December 2014.
All possible performance measures that were identified by this process were structured using the PICO framework (where P stands for population/patient; I for intervention/indicator; C for comparator/control; and O for outcome) to inform searches for available evidence to support the performance measures. This process resulted in 67 possible performance measures and 108 PICOs.
Due to the timeframe for this first initiative and the wide range of pathology in the UGI tract, the working group had to prioritize general UGI endoscopy topics within the abundance of proposed performance measures and PICOs. As part of this prioritization, PICOs that were concerned with areas where guidelines were already available or under development were omitted.
We also excluded PICOs that focused on: the assessment of effectiveness, or comparative effectiveness, of specific treatments (e.g. administration of proton pump inhibitors (PPIs) before endoscopy for acute bleeding, percentage of patients undergoing endoscopic resection in Barrett's esophagus with high grade dysplasia (HGD) before ablation); legal or local regulation (informed consent); histopathology (e.g. the need for confirmation/revision of a diagnosis of dysplasia by an independent pathologist); and service working group issues (e.g. adequate management of anticoagulants, sedation, etc.).
The initial priority list was developed during a faceto-face meeting on 14 February 2015. In total, 44 PICOs were retained as the basis for literature searches. Several disease-specific performance measures were also developed (Barrett's esophagus, intestinal metaplasia in the stomach, and squamous cell cancer (SCC) in the esophagus).
The PICOs, and the clinical statements derived from these which were organized into eight domains on the basis of their clinical applications, were adapted and/or excluded during the iterative rounds of comments and suggestions from the working group members during the Delphi process. The evolution and adaptation of the different PICOs and clinical statements during the Delphi process can be reviewed in the Supplementary Material. In total, working group members participated in four rounds of voting to agree on the performance measures in predefined domains and their respective thresholds, which are discussed below. The agreement that is given for the different statements refers to the last voting round in the Delphi process. A statement was accepted if at least 80% agreement was reached after a minimum of two voting rounds.
The performance measures are displayed in boxes under the relevant domain. Each box describes the performance measure and the rationale behind its adoption, the agreement on acceptance during the modified Delphi process, and the grading of the available evidence, along with details of how the score should be measured and the desired threshold.
During the Delphi process, the Quality Improvement Committee (QIC) chairs distinguished key performance measures from minor performance measures to assist service providers with decisions about the implementation of performance measures in their endoscopy services. Reasons to qualify a performance measure as minor included the measure being very disease specific (e.g. detection of neoplasia during surveillance of Barrett's esophagus or gastric intestinal metaplasia) or that its implementation might be relatively difficult and dependent on the availability of adequate software for auditing of the performance measures. The division and allocation of performance measures to key and minor performance measures was agreed by the UGI working group in an additional face-to-face meeting in April 2016.
The number of cases that need to be audited to adequately assess if the threshold for a certain performance measure is reached can be calculated by estimating the 95% confidence intervals (CIs) for a predefined threshold and variable sample size (see Appendix 1) . For reasons of practicality and feasibility when implementing an audit, the working group agreed that 100 procedures (or all, if <100 procedures had been performed) should be measured to assess the performance measure. Ideally this should be done at an individual procedure level but, as this requires robust and sophisticated software, we suggest that the assessment is first performed at a service level. If problems are detected at a service level, further analysis at an individual level is then required to identify possible targets for improvement.
Performance measures for UGI endoscopy
In the first round of development, the working group accepted 11 performance measures in total, after a total of four voting rounds in the modified Delphi process. The evidence quality (assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria) 6 for most of these performance measures is low; however, this does not indicate that a performance measure is not important.
Taking into account both the feasibility of implementation and the possible impact on diagnostic quality and patient outcome, we identified six key and five minor performance measures ( Figure 1 and Table 1 ). Nevertheless, all the performance measures were deemed valuable by the working group members and were obtained after a rigorous process, as described above. From a practical viewpoint, it may be desirable to implement the key performance measures first in those units that are not presently monitoring any performance measures. Once a culture of quality measurement is accepted and software is available, the minor performance measures may then further aid monitoring of the quality of UGI endoscopy.
All of the performance measures are described below, according to the domain to which they are attributed. The PICOs and statements that were used during the modified Delphi process to develop the performance measures can be found in the Supplementary Material. The statement numbers correspond to those used in Supplementary Material.
Domain: pre-procedure
The acceptance of this performance measure (Box 1) is based on agreement with the following statements:
. Patients referred for scheduled UGI endoscopy should be fasting (statement number N1.1 (see Supplementary Material)) Agreement: 100%. . Patients referred for UGI endoscopy should be fasting for solids for at least six hours prior to the procedure. (N1.2) Agreement: 91%. . Patients referred for UGI endoscopy are allowed to take in water until two hours prior to the procedure. (N1.3) Agreement: 100%.
Two studies were found that addressed these instructions and the duration of fasting prior to a scheduled UGI endoscopy. 7, 8 In both studies, the authors mainly assessed the fasting time for liquids. The fasting time for solids was at least six hours prior to the endoscopy in both studies, with a good effect on visibility during endoscopy.
In the study by Koeppe et al., 7 general discomfort was reported less frequently by patients who had a drink of water (200 ml) two hours before the procedure than in those who were fasting for solids and liquids for a full eight hours (18% vs 42%; p ¼ 0.010). Even though the endoscopists subjectively observed more liquid in the stomach of the former group, no cases of aspiration were observed in the sample of 50 lightly sedated patients.
De Silva et al. 8 also reported lower discomfort scores when water ad libitum was allowed until one hour before the procedure (recorded volumes drunk were 200-410 ml) compared with no water being allowed during a six-hour pre-endoscopy fast (5.6 vs 9.7; p < 0.0001). No significant differences were found for complications and safety outcomes, apart from a significant difference in the volume of retained fluid in the gastric fundus, this being greater when water was drunk until one hour prior to the procedure, which was performed without sedation. Again no cases of aspiration were observed.
The outcome ''incomplete examination'' was not reported in the retrieved studies. The outcome ''good or normal visibility of gastric mucosa'' could be used as an indirect outcome for the evaluation of incomplete examination. This outcome was consistently high after both two hours/one hour minimum of no fluids and nil by mouth for at least six hours (96% vs 98% 7 and 93% vs 100%, 8 
respectively).
Although no data from the two available studies directly assessed the duration of fasting for solids, it appears that an interval of at least six hours is safe and effective for UGI endoscopy in patients without any history or predisposing factors for delayed gastric emptying. For endoscopies that are planned to be performed in the afternoon, patient satisfaction may be increased if a small breakfast is allowed.
Unlike with colonoscopy, we do not have a standardized scale to measure ''gastric preparation'' for UGI endoscopy. We advise that the contents of the stomach, such as food residues, blood, bile, or the presence of bubbles, should be reported, along with information on whether a waterjet system was used to improve mucosal visualization. Just recording this as a surrogate performance measure may however omit patients that are sent home again because they did not receive fasting instructions. Recording that proper instructions were given should therefore be done prior to the endoscopy itself and this could be included in the pre-assessment part of the endoscopy report (together with, for instance, the informed consent). This would mean that patients who show up for endoscopy having not received proper instructions and therefore have their endoscopy cancelled should be included in any audits of this performance measure.
Domain: completeness of procedure
The acceptance of this performance measure (Box 2) is based on agreement with the following statements:
. A UGI endoscopy in a patient who has not undergone a previous gastroscopy within the last three years should include inspection of the esophagus, stomach, and duodenum, and should last for at least seven minutes from intubation to extubation. (N2.2) Agreement: 80%. . Although the evidence to support this is of very low quality, the major duodenal papilla should be visualized and photographed in all UGI endoscopies in patients with normal anatomy when a full examination is intended. (N2.1) Agreement: 73%.
In contrast to colonoscopy, there is a paucity of data on the assessment of a complete procedure. As a definition, ''reaching the duodenum'' seems too trivial: it does not really reflect endoscopic competence as it is easy to achieve; there is no data comparable to cecal intubation rate in the colon that supports its relationship to better disease detection.
During the discussions of the working group, there was a strong emphasis on trying to define this performance measure and searching the literature for an anatomical landmark or finding that might be related to disease detection. We formulated several PICOs to assess whether reaching any specific anatomical landmark yielded a better rate of diagnosis. One may speculate whether documentation that the major papilla has been visualized can serve as an auditable performance measure for completeness of the procedure in a patient referred for a complete UGI endoscopy. Analogous to cecal intubation, it cannot be achieved in all endoscopies and is less trivial than reaching the second portion of the duodenum. In the absence however of any data to support this, no consensus was reached on this statement (only 73% agreement) and the working group therefore formulated this as one of the research priorities ( Table 2) .
We did however find one study that aimed to evaluate whether the length of time spent on UGI endoscopy improved the diagnostic yield. This was a retrospective cohort study by Teh et al. 9 that aimed to determine the 1 Evidence grading Very low quality diagnostic yield for early neoplastic lesions in the stomach. The study included 837 symptomatic patients with no history of gastric cancer who underwent a first diagnostic endoscopy by one of 16 endoscopists. The mean examination time for the 224 examinations without any abnormal findings or biopsies taken was 6.6 min, which allowed the definition of a cut-off time of 7 min to distinguish between ''slow'' versus ''fast'' procedures. Afterwards, in a retrospective evaluation of the 837 endoscopies, they concluded that a ''slow'' endoscopist (who took on average at least seven minutes to perform a normal endoscopy) was twice as likely to detect high risk gastric lesions, defined as biopsy evidence of intestinal metaplasia, gastric atrophy, gastric dysplasia, or cancer (odds ratio (OR) 2.50, 95% CI 1.52-4.12) and three times as likely to detect a case of dysplasia or cancer (OR 3.42, 95% CI 1.25-10.38) than a ''fast'' endoscopist (who took fewer than seven minutes on average). A similar concept of measuring length of time for inspection, but in the specific context of Barrett's esophagus, has shown increased detection of dysplasia with an inspection time of one minute per cm of Barrett's esophagus. 10 Only one study has evaluated the correlation between increased detection of gastric dysplasia or gastric cancer and other UGI endoscopic diagnoses. 11 Park et al. retrospectively analyzed 54,889 records of patients who underwent a screening UGI endoscopy, performed by 66 experienced endoscopists, from 2006-2013 in a single center in Korea. Any diagnoses of reflux esophagitis, Barrett's esophagus, atrophic gastritis, intestinal metaplasia, erosion, ulceration, polyps, subepithelial lesions, xanthoma, angiodysplasia, or a diverticulum were recorded and the relevant records were re-evaluated with respect to increased detection of early gastric neoplasia. In multivariate analysis, the detection rates of gastric subepithelial lesions and gastric diverticula were independently associated with the detection rate of early gastric neoplasms.
The acceptance of this performance measure (Box 3) is based on agreement with the following statements: No data exist to support the view that photodocumentation of all normal anatomical landmarks and abnormal findings will improve diagnostic yield. However, photodocumentation should be considered a general quality improvement in comparison with previous reports that were made before dedicated reporting software was available. Most endoscopic systems now enable digital picture acquisition, therefore the working group strongly agreed on the inclusion of digital photography in reports. This measure is supported by endoscopic societies and experts suggest it might be an indirect quality indicator for careful inspection of the digestive lumen. [12] [13] [14] The minimum number of pictures to be collected, combining relevance and applicability, in a normal endoscopic examination should be 10, namely: proximal esophagus, distal esophagus, Z line and diaphragm indentation, cardia and fundus in inversion, corpus in forward view including lesser curvature, corpus in retroflex view including greater curvature, angulus in partial inversion, antrum, duodenal bulb, and second part of duodenum. The working group suggested that it may be desirable to document more extensively in specific surveillance examinations, such as for Barrett's esophagus (e.g. one picture per cm of Barrett's esophagus), 10 or where there are extensive gastric premalignant conditions (e.g. 21 pictures of the stomach). 13 In addition, several validated classifications have been developed for specific pathologies. The working group agreed that the use of these classifications in conjunction with photodocumentation improves comparability and accurate information exchange among gastroenterologists, both in the clinical setting and for investigational purposes. In the UGI tract, this is especially true for the Los Angeles classification for the reporting of reflux esophagitis and the Prague classification for Barrett's esophagus. [15] [16] [17] [18] Implementation of this performance measure is inevitably dependent on the availability of image acquisition and software to incorporate images into the report. Because this performance measure simplifies and improves communication between different endoscopists, implementation of appropriate software should be prioritized by hospital policy makers. The working group recognizes that gastroenterologists performing procedures mainly in their own surgeries will often struggle to find a reasonable way to be reimbursed for the considerable cost of this software.
Domain: identification of pathology
The acceptance of this performance measure (Box 4) is based on agreement with the following statements: What is the percentage detection of dysplasia in a Barrett's surveillance program in a general endoscopy practice? What is the percentage of intestinal metaplasia in the stomach throughout Europe in a general endoscopy practice? Could visualization of the papilla of Vater be used as a measure for a complete and high quality endoscopy? Does the percentage of endoscopies where the papilla is visualized correlate with a higher general diagnostic yield during UGI endoscopy? What is the relationship between inspection time during UGI endoscopy and diagnostic yield?
The role of endoscopy in redefining diseases of the UGI tract Endoscopy with or without biopsies Do biopsies alter the management of patients with Barrett's esophagus or eosinophilic esophagitis? What is the role of advanced imaging in a general endoscopy practice for dysplasia detection in:
Barrett's esophagus Squamous cancer detection in high risk patients
Intestinal metaplasia in the stomach? Can automated image analysis remove the need for biopsies and guide the management of patients with:
Barrett's esophagus Intestinal metaplasia of the stomach Celiac disease? What is the role of teaching modules in training endoscopists in image interpretation and lesion recognition?
. The entire procedure for surveillance of intestinal metaplasia should last at least seven minutes from scope intubation to scope extubation of the patient. (N6.1). Agreement: 100%. . A UGI endoscopy in a patient who has not undergone a previous gastroscopy within the last three years should include inspection of the esophagus, stomach, and duodenum, and should last for at least seven minutes from intubation to extubation. (N2.2) Agreement: 80%.
The evidence for this performance measure is mainly derived from the study by Teh et al. 8 By using a cut-off time of 7 min per endoscopy, from intubation to extubation, endoscopists performing above the cut-off (i.e. longer inspection times) detect two times as many high risk gastric lesions (intestinal metaplasia, gastric atrophy, gastric dysplasia, or cancer) and three times as many dysplastic lesions and gastric cancers. The study did not evaluate differing diagnostic yields in the esophagus or duodenum between endoscopists but it provides evidence for the stomach that is comparable to that for inspection times in the colon. 18 The interval of three years in the statement from the Delphi process stems from the suggestion of the European consensus on ''Management of precancerous conditions and lesions in the stomach (MAPS)'' guideline. 19, 20 The three-year interval was suggested among experts to be the best clinically applicable interval for endoscopic surveillance of extensive atrophy and/or extensive intestinal metaplasia. This three-year interval strategy has been shown more recently, in a European population between 50-75 years of age, to be cost-effective as a surveillance strategy. 21 The acceptance of this performance measure (Box 5) is based on agreement with the following statements:
. Abnormal findings should be reported according to available internationally validated and standardized terminology. (N3.2) Agreement: 100%. 1
Evidence grading Very low quality evidence
The quality of endoscopy is closely related to the quality of the report and the use of standardized terminology enables better communication between endoscopists and unequivocal discrimination of disease-related findings.
The working group considered accurate reporting as one of the main topics for quality assurance. Besides reporting and documentation of anatomical landmarks, the correct use of available and validated terminology for specific diseases was considered to be a cardinal point for quality improvement. It enables the gathering of sound epidemiological data and is a prerequisite for auditing the quality of endoscopic reports. Although the literature searches for the PICOs did not render any evidence in terms of higher diagnostic yield or proven efficacy for better physician interaction and communication, the statements on implementing standardized terminology as a quality measure for accurate reporting all reached 100% agreement. Recording of the final diagnosis of the endoscopy is fundamental to allow the calculation of this performance measure and therefore its implementation may be more difficult If the threshold is not reached at a service level, the service should assess whether technical support is sufficient to make a search for auditable endoscopies feasible, based on software that allows the diagnosis on an endoscopy report to be searched If the threshold is not reached for an individual endoscopist, feedback should be provided, followed by close monitoring for 6 months to assess the performance of the individual endoscopist After evaluation and adjustment, close monitoring should be performed with a further audit within 6 months Consensus agreement for performance measure 91% PICO numbers (see Appendix 2)
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Evidence grading Very low quality
The Paris classification is a uniform and relatively well established endoscopic classification for early neoplastic lesions, 22, 23 with clinical value in terms of the prediction of the risk of submucosal invasion and therefore eligibility for endoscopic treatment; 23 however, little is known about the interobserver agreement of this classification. Recently, the value of this classification system has been questioned in an interobserver study for polyp assessment in the colon, which showed a Kappa value of 0.42 and a mean pairwise agreement of 67%. 24 This study indicates that further research is clearly necessary to assess the applicability of the Paris classification or perhaps to simplify it.
The Los Angeles classification for erosive reflux disease was validated when it was introduced in 1996 25 and demonstrated that interobserver agreement for the assessment of minimal changes, mucosal breaks, demarcated areas of slough or erythema, and complications was good. Because of the availability of interobserver data and the fact that this classification is now used most widely, the working group opted to implement the Los Angeles classification as the standard for endoscopic assessment of reflux disease. 25, 26 Similarly, the Prague classification is a relatively straightforward and reproducible score, which enables better communication between endoscopists. The score has been validated among experts 18 and in two additional studies among trainees and community-based endoscopists, strengthening the value of the Prague classification for the accurate description of Barrett's esophagus and the length of the hiatal hernia. 27, 28 The ESGE guideline on the diagnosis and management of nonvariceal UGI bleeding has strongly recommended the uniform use of the Forrest classification, as used in several studies assessing the risk for peptic ulcer bleeding and rebleeding. 29, 30 Therefore it is clinically important that this classification is used in the endoscopy report in order to ascertain the correct clinical management after endoscopy for UGI bleeds. 31 Other classification systems that should be implemented are Zargar's classification for caustic esophagitis, 32 the Baveno classification for grading of esophageal varices, 33, 34 and Spigelman's classification for duodenal polyps in FAP syndrome. 35, 36 Although there is less data available in terms of reproducibility, these scoring systems are relatively simple to apply and have an intrinsic clinical value in terms of patient management and follow-up.
The working group accepted that although agreement was reached about the use of the aforementioned standardized terminology in the modified Delphi process, its implementation may be not so easy. In particular, in order to provide data that will enable this performance measure to be audited, there is a requirement for an adequate electronic reporting system that can match a diagnosis (e.g. bleeding duodenal ulcer) to the standardized terminology being used (Forrest classification). A prerequisite of such a reporting system is that it would permit automated queries to be run at regular intervals and feedback to be supplied to individual endoscopists. Outputs from such reporting systems can help to improve the performance for this measure: for instance, the system can be adapted to provide a reminder of the criteria of the relevant classification system and so that a report cannot be validated unless, when a particular diagnosis has been made, the corresponding terminology is used. If such a system is in place, systematic electronic reports are encouraged and the over-riding of this requirement by the endoscopist should be discouraged.
The acceptance of this performance measure (Box 6) is based on agreement with the following statement:
. Inspection time in the esophagus for surveillance of a Barrett's segment should be at least 1 min/cm of circumferential extent of Barrett's epithelium. (N4.5) Agreement: 90%.
No studies were found that have directly addressed the comparison between measuring or not measuring the inspection time. One study aiming to determine whether the inspection time in Barrett's esophagus correlated with the detection of endoscopically suspicious lesions and/or Barrett's esophagus-associated neoplasia, namely HGD or early adenocarcinoma (EAC), was considered partially relevant. 10 It was a cross-sectional post hoc analysis of data from a multicenter, prospective clinical trial of 112 patients that investigated the performance of novel imaging techniques for dysplasia detection during Barrett's esophagus surveillance. The study found that greater proportions of patients had an endoscopically suspicious lesion with increasing inspection times (2 min, 30%; 3-4 min, 35.5%; 5-6 min, 82.1%; 7 min, 84.6%; p < 0.001) and a greater proportion were found to have HGD/EAC (2 min, 15%; 3-4 min, 32.3%; 5-6 min, 46.4%; 7 min, 69.2%; p ¼ 0.001). The study suggested that an inspection time of 1 min/cm of Barrett's esophagus resulted in increased detection of neoplasia.
Although this study had certain limitations and did not reflect the real-life prevalence of Barrett's esophagus dysplasia in a community-based hospital, the working group members agreed to support this performance measure with a high degree of agreement. In contrast to the detection of colon polyps, where a solid scientific basis seems to exist with regard to the measurement of inspection time during withdrawal 3, 19 as a performance measure, for UGI endoscopy there is a paucity of scientific data. 9,10 Nonetheless, it seems reasonable to assume that a lengthier inspection of Barrett's esophagus may result in better lesion detection.
The optimal inspection time also includes rinsing the esophagus sufficiently to improve visualization, proper sedation and patient tolerance, and the use of high definition endoscopy (i.e. high definition endoscopes connected to high definition monitors using a high definition signal). At this time, there are no data to support the systematic use of any advanced imaging technique, such as chromoendoscopy or electronically enhanced endoscopy, 37, 38 but neither is there harm in applying them when available. In the recent Benign Barrett's and CAncer Taskforce (BOB CAT) consensus, it was suggested that these techniques should be used in experienced hands only. 4 The implementation of this performance measure is again dependent on the availability and development of an electronic reporting system; however, once this is in place, it should be easy to comply with. One of the research priorities should be to elucidate whether there is a correlation between inspection time and increased neoplasia detection in Barrett's esophagus in a general secondary-care setting.
The acceptance of this performance measure (Box 7) is based on agreement with the following statement:
. Accurate use of chromoendoscopy in patients with a history of ENT or lung tumors who are treated with curative intent results in a higher diagnostic yield for Eight studies addressed this clinical question specifically in patients with a history of head and neck tumors by comparing conventional white-light endoscopy with Lugol chromoendoscopy. [39] [40] [41] [42] [43] [44] [45] [46] Because this is a screening examination by a minimally invasive technique, from a clinical point of view it only makes sense to perform it in patients who have been previously treated with curative intent for their primary tumor. For the diagnosis of SCC, five of the studies showed improvements in the rates of diagnosis, mostly for early cancers, ranging from 20-100% of detected lesions, 39, 41, 42, 45, 46 while all eight studies showed increased yield for dysplasia ranging from 33-100% of lesions. The overall incidence rates of lesions in this particular high risk group of patients were 2-9% for dysplasia and 1-5% for cancer after Lugol chromoendoscopy.
The usual technique in UGI endoscopy uses esophageal staining with 10-20 ml of a 2% Lugol dye solution applied by a spray catheter or directly by the biopsy channel of the endoscope, with the esophageal examination being repeated two minutes later. In view of the fact that Lugol chromoendoscopy is a cheap and relatively easily applied technique, for which the available evidence is of moderate quality, the working group reached a high degree of agreement on the acceptance of this performance measure.
Domain: management of pathology
The acceptance of this performance measure (Box 8) is based on agreement with the following statement:
. 
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Evidence grading Moderate quality quadrant biopsies taken every 2 cm along the extent of the circumference of the Barrett's esophagus 47 all collected in different containers per level and per lesion. This is generally accepted in guidelines to be the standard method for Barrett's esophagus surveillance. 37, 38, 48 The acceptance of this protocol dates back to several observational -sometimes contradictory -studies, which were mainly performed in an era prior to advanced imaging, that suggested better detection of neoplasia and possibly a reduction in mortality. In a retrospective cohort study including 362 patients with 3 cm Barrett's esophagus undergoing endoscopic surveillance, 180 patients received a systematic Seattle biopsy protocol and 182 subjects received a non-systematic biopsy strategy. 49 The Seattle protocol detected significantly more low grade dysplasia (LGD; 18.9% vs 1.6%; p < 0.001) and HGD (2.8% vs 0%; p ¼ 0.03). In the non-Seattle biopsy group, three patients died of 50 reported a cohort of patients treated endoscopically for early Barrett's esophagus neoplasia and found that those without a prior diagnosis of dysplasia were more likely not to have undergone the Seattle biopsy protocol. In the era prior to an established endoscopic treatment of early Barrett's esophagus neoplasia particularly, controversy existed as to whether an intensified protocol better predicted the presence of cancer in comparison to a less intensive protocol. Reid et al. 47 intensified the classical protocol to four quadrant biopsies every 1 cm for patients followed up after a diagnosis of HGD and suggested that a 2 cm biopsy protocol would miss 50% of the cancers. In contrast, Kariv et al. 51 found that a 2 cm interval for the biopsy protocol was sufficient to detect cancer prior to esophagectomy. Studies using advanced imaging techniques in experienced referral centers suggest that in the future there may be a role for new techniques to replace the Seattle protocol, but currently there are insufficient data to support this. 38 Because of the widespread acceptance of this protocol in all guidelines, the working group agreed fully that, despite the low quality evidence, adherence to the Seattle protocol could serve as a valuable performance measure to monitor UGI endoscopy practice. It is important to emphasize that this parameter is only applicable in the surveillance setting.
From a practical viewpoint, containers should be labeled according to the level at which the biopsy was taken. The working group suggests a coding system that unequivocally allows a location to be allocated to each container using a two number combination ''xxyy.'' In this ''xx'' refers to the distance from the incisors and ''yy'' to the location on a clock with the three o'clock position corresponding to the lesser curvature (scope in neutral position) and with 00 indicating random biopsies. For instance, 4000 would indicate random biopsies taken at 40 cm from the incisors, while 3805 stands for a targeted biopsy taken from a lesion at 38 cm from the incisors and in the five o'clock position.
The acceptance of this performance measure (Box 9) is based on agreement with the following statements:
. For the diagnosis of intestinal metaplasia and
Helicobacter pylori, at least two biopsies of the antrum and two biopsies of the corpus should be taken. (N6.2) Agreement: 80%. . In addition to two biopsies of the antrum and two biopsies of the corpus, a biopsy in the incisura is demanded for both the Operative Link for Gastritis Assessment (OLGA) and Operative Link The MAPS guideline recommends that for the assessment of extension of gastric atrophy and intestinal metaplasia, beyond performing the best available endoscopy in terms of technology and the time for inspection, at least two biopsies must be taken from the antrum and two from the body of the stomach, and these must be placed into separate containers. 20 This recommendation is in concordance with the minimum standards for pathology as described in the OLGA or OLGIM grading systems for gastritis. 52, 53 These grading systems require an additional separate biopsy from the incisura. However, several studies have addressed the issue of the number of biopsies and inconsistency exists regarding the incisura biopsy in terms of increased diagnostic yield. [54] [55] [56] [57] [58] [59] De Vries et al., 54 in a prospective cohort study comparing different numbers of non-targeted biopsies (five, seven, or nine) to the 12-biopsy scheme (used as the reference), found that, in a population with a low gastric cancer risk, at least nine non-targeted biopsies should be taken from the cardia, lesser curvature of the corpus, angulus, and antrum to achieve the best diagnostic yield. Guarner et al. 55 compared protocols of three, five, and seven biopsies and found that the five-biopsy protocol reached 100% sensitivity for H. pylori, 96% for atrophy, and 95% for metaplasia and dysplasia.
Eriksson et al., 56 in consecutive patients from a similar low risk population, took six biopsies (two from the antrum, two from incisura, and two from corpus). While no patients showed dysplasia in their incisura biopsies, these biopsies were the only ones to show intestinal metaplasia but, as this was seen in 3.3% of cases only, they concluded that routine biopsy of the incisura would provide little additional information. El-Zimaity et al. 57 also found that intestinal metaplasia was missed in more than 50% of cases, and that this was independent of the site of biopsy and that no set or site of biopsy specimens, including the incisura, could reliably exclude the presence of intestinal metaplasia.
On the other hand, Isajevs et al. 58 assessed the relevance of the incisura biopsy and concluded that, if the incisura biopsy was excluded, down-staging would occur in 18% of cases for the OLGA classification and 4% for the OLGIM, resulting in a 30-35% downgrading from high risk to low risk in terms of the OLGA/OLGIM stages. Finally, Stolte et al., 59 using the same five-biopsy protocol, concluded that the presence of antral mucosa at the incisura was associated with considerably more severe gastritis (14% atrophy and 20% intestinal metaplasia in the antrum) than the presence of corpus mucosa at the incisura (only 2% atrophy and 6% intestinal metaplasia).
From a practical and clinical point of view, five nontargeted biopsies overall, comprising two from the antrum, one from the incisura, and two from the corpus, seems to provide the most relevant information without compromising clinical applicability.
We do realize that the MAPS guidelines address more than just taking biopsies to assess the extent of atrophy or metaplasia. However, the emphasis of this performance measure lies in identifying patients at risk that should be followed up. It is obvious that the MAPS guidelines remain applicable independent of the proposed performance measures. Furthermore, depending on the prevalence of a certain disease, the attention that is given to the corresponding performance measure may vary geographically throughout Europe. For instance, follow-up and adequate diagnosis of Barrett's esophagus will be more important in Western Europe, whereas intestinal metaplasia of the stomach may carry a higher interest in Eastern and Southern Europe.
Domain: complications
The acceptance of this performance measure (Box 10) is based on agreement with the following statements:
. The perforation rate following polypectomy or endoscopic mucosal resection (EMR) in the Record the procedures in which gastritis is detected, and where screening for HP gastritis and intestinal metaplasia are performed Record if at least two biopsies from the antrum and two biopsies from the corpus were taken and placed into two different jars for histology (MAPS guidelines) Denominator: all endoscopic examinations where assessment of the gastric cancer risk is considered clinically relevant (see exclusion criteria) Numerator: procedures in the denominator in which at least two biopsies from the antrum and two biopsies from the corpus were taken and placed into two different jars Exclusions: -Therapeutic procedures -UGI with normal gastric findings -Gastric findings that do not need the application of guidelines -Follow-up of intestinal metaplasia -Work-up endoscopy for known gastric dysplasia Calculation: proportion (%) Level of analysis: For this domain, we specifically addressed adverse events and harms for procedures that are generally and frequently carried out in all endoscopic units. We focused on the perforation and bleeding rate after Savary or pneumatic dilation and endoscopic resections in the UGI tract.
A total of 37 studies were included for complications after dilation. They generally seemed to have prospectively recruited patients, but the information was often not very clear. Overall 3263 patients were included, of which 2202 were adults and 1061 children. Overall 8524 Savary and 5491 balloon dilations were performed. None of the studies reported cases of serious bleeding, but the majority of the studies did not assess this outcome. Perforations occurred in 0.98% of cases of balloon dilation and in 0.68% of cases of Savary dilation. Similarly, for adverse events after endoscopic resection, 38 papers were included. The perforation rates were 1.6%, 0.98%, and 1.61% in the esophagus, stomach, and duodenum, respectively, with bleeding rates of 4%, 6.9%, and 9.2%, respectively.
Although the literature search yielded the highest number of included papers for these PICOs, including several systematic reviews, the working group could not agree on a predefined maximal allowance for these post-procedural adverse events. This was attributed to the fact that the overall quality of the evidence was graded as very low, being retrospective in nature and with it not always being clear if patients had been consecutively included in the studies. For these indications, the data were therefore not sufficiently adequate to decide on a threshold that would be used to audit an endoscopy service. Indeed, the final result would to a large extent be determined by the denominator, and it is therefore not clear what the incidence of adverse events would be in individual centers with lower numbers.
The working group did however reach agreement on the fact that patients should be monitored for adverse events or harms after therapeutic interventions. This monitoring will generate more realistic numbers, which in turn can be used to determine a minimum number of procedures per service or operator for these interventions (see below).
Domain: procedure numbers
In the absence of any evidence regarding the number of procedures needed for an individual to be certified to perform UGI endoscopy, we were not able to set any minimum numbers (Box 11).
Any recommendation in terms of the minimum annual number of procedures per endoscopist that are required to maintain adequate levels of quality would need to be based on an established strong association of poor quality with a minimum threshold number of procedures performed per year; however, such data are unavailable. The working group anticipates that, with application of the present performance measures, information will come to light to clarify whether such a concept does apply to diagnostic and/or therapeutic UGI endoscopy.
Domain: patient experience
Patient experience and satisfaction are important outcome measures of endoscopy in general. The UGI working group concluded that this should be measured after any endoscopic procedure. In general, there is lack of evidence assessing the effect of certain logistic or procedural aspects on patient's satisfaction and experience (Box 12).
The working group members concluded that this is a domain for research and, because it applies to all forms of endoscopy within an endoscopy service, it was suggested that this particular domain resides more under the service working group. Undoubtedly, several measures can be undertaken to improve patient's experience. For instance, providing an information brochure on UGI endoscopy at least one day prior to the procedure has been shown to result in less anxiety beforehand and greater satisfaction after the procedure. 119 Domain: post-procedure
The acceptance of this performance measure (Box 13) is based on agreement with the following statements:
. The incidence of HGD in a Barrett's surveillance program, when diagnosed by at least two specialist gastrointestinal pathologists, should not be lower than 0.1% per year. (N4.8) Agreement: 70%.
As with the colonic adenoma detection rate that is used as a performance measure for colonoscopy, it would seem appropriate for UGI endoscopy to use a minimum detection rate for dysplasia in the surveillance of Barrett's esophagus. From the PICO search, 28 studies with 49,815 patients were finally included. 49, All of the studies included patients with a diagnosis of Barrett's esophagus who underwent regular surveillance. Of the 28 studies, 17 were retrospective or prospective studies assessing prevalence of LGD and HGD at baseline and the incidence of LGD and HGD during follow-up. The length of follow-up ranged from 1.6-6 years, with a median of four years. The remaining studies were cross-sectional studies that reported prevalence data, although often they had objectives other than the assessment of prevalence. These cross-sectional studies had, on average, smaller samples sizes ranging from 30-295 patients, with a median of 80 patients included. Sample sizes of the cohort studies ranged from 121-42,207 included patients, with a median of 277 patients.
Although the quality of the evidence was rated as moderate, because of inconsistency in the data, no agreement was achieved in the Delphi process on a specific cut-off for the detection of dysplasia. Indeed, the prevalence of LGD ranged from 0.6-33.3% in the cross-sectional studies and from 0-37.2% in the cohort studies, with the prevalence of HGD ranging from 0-14.6% and 0-23.9%, respectively. The incidence of LGD and HGD ranged from 2-34.5% and from 0-5.8%, with median values of 14.7% and 2%, respectively. Although no agreement was obtained on the cut-off for dysplasia detection, the working group members agreed on the fact that the incidence of dysplasia in a Barrett's esophagus surveillance program should be monitored in order to obtain more consistent and accurate epidemiological data. When these data become available, a more realistic cut-off value may be determined, taking into account geographical differences and other risk factors of progression.
General conclusions, research priorities, and future prospects
This paper describes the first performance measures generated by evidence-based consensus that can be used for UGI endoscopy. We used a systematic and scientifically sound methodology to substantiate the proposed measures with available evidence where possible. As this is a largely unexplored field, most of the generated evidence is, as expected, graded as low quality. This in itself generates an important research priority, which is merely to measure the proposed performance measures and to evaluate whether they do in fact influence health outcome.
The working group identified several additional research priorities. These are listed in Table 2 and will be addressed in an additional manuscript from the ESGE research committee.
The first step now is to implement these new performance measures into endoscopy practice over Europe. This is the only way forward that can evaluate the actual value of the performance measures and allow their adaptation in future. The working group members emphasize that all performance measures were perceived as important but, in order to facilitate their implementation, we made a distinction between key performance measures and minor performance measures. Although this distinction is somewhat arbitrary, attention was paid especially to patient safety, patient service (increasing diagnostic yield), and the feasibility of implementation. Indeed, some of the performance measures may be more difficult than others to implement or, because of geographical differences in disease prevalence, may be less relevant in certain centers.
The implementation of performance measures is important to identify services and individual endoscopists with lower levels of performance. We encourage individual endoscopists, as well as heads of endoscopy units, to start the implementation of these performance measures without delay. At a unit level, this may well mean investing in hardware to accommodate a more efficient auditing process.
Through individual feedback, measures can be taken to improve quality to rise above the proposed minimum thresholds. This should not be regarded as a ''big brother'' strategy with the goal of penalizing specific endoscopists, but rather as a tool to improve the quality of endoscopy in general, improve patient outcomes, and provide training and assistance where needed.
A second barrier may be the financial repercussions of implementing a quality control system. We want to encourage hospital management to support the implementation of these performance measures in their endoscopy services. We think that in an era where general hospital accreditation is becoming more and more important, hospital administrations will be more inclined to support such actions. Moreover, we owe it to our patients to overcome individual or financial barriers to ensure that endoscopy services are of the highest quality and to set research priorities to gather data that will inform the next generation of performance measures.
Supplementary Material
The evolution and adaptation of the different PICOs and clinical statements during the Delphi voting process can be viewed in Supplementary Material.
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